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Background. People living with HIV (PLWH) appear to be at increased risk of cardiovascular disease (CVD), and this is pos-
sibly more pronounced in women living with HIV (WLWH). In the general population, men are more likely to develop obstructive 
coronary artery disease (CAD), and women often present with a nonobstructive pattern with cardiac microvascular dysfunction. 
We investigated cardiac microvascular function in men and women living with HIV and tested for association with cytomegalovirus 
(CMV) immunoglobulin G (IgG), as this has been associated with CVD in PLWH.
Methods. In a cross-sectional study, 94 PLWH on antiretroviral therapy were scanned with 82Rb positron emission tomography/
computed tomography at rest and during adenosine-induced stress, which enables the quantification of the myocardial flow reserve 
(MFR). CMV IgG was measured in plasma.
Results. WLWH had significantly lower MFR compared with men living with HIV (MLWH; P = .003), and >45% of the women 
had an MFR indicative of cardiac microvascular dysfunction, whereas this was only true for 24% of men (P = .03). CMV IgG con-
centrations were inversely associated with MFR among WLWH but not MLWH (P = .05 for interaction).
Conclusions. In this first study comparing MFR in women and men living with HIV, we found that WLWH had significantly 
lower MFR than MLWH and 45% of the women had cardiac microvascular dysfunction despite younger age and lower cardiovas-
cular risk. Furthermore, CMV IgG was inversely associated with MFR among women but not men. This calls for attention to CVD 
among young WLWH even with low cardiovascular risk.
Keywords. cardiac microvascular dysfunction; cytomegalovirus; cardiovascular disease; HIV.
 
People living with HIV (PLWH) appear to be at increased risk 
of cardiovascular disease (CVD), with manifestations such as 
myocardial infarction (MI) [1] and heart failure [2]. Some stud-
ies suggest that this risk is even more pronounced in women 
living with HIV (WLWH) compared with men living with HIV 
(MLWH), but the mechanism behind this sex-based difference in 
risk is unclear [2–5]. The pathogenesis behind the increased risk 
of CVD associated with HIV infection is not fully understood but 
seems to be related to a higher prevalence of “traditional” cardio-
vascular risk factors, the antiretroviral therapy (ART) and immu-
nologic changes involved in chronic infection with HIV [6]. 
Furthermore, cytomegalovirus (CMV) infection has been asso-
ciated with risk of cardiovascular disease in the general popula-
tion [7], and as co-infection with CMV is very common among 
PLWH [8], it has been speculated that CMV could contribute to 
CVD among PLWH. Indeed, both CMV-specific T-cell responses 
and CMV immunoglobulin G (IgG) have been associated with 
vascular changes among PLWH [9, 10].
Studies from the general population find that the pathogene-
sis and phenotype of CVD may differ between men and women 
[11], where men are more likely to develop flow-limiting ath-
erosclerotic coronary artery disease but women are more likely 
to present with a nonobstructive pattern and a high degree of 
cardiac microvascular dysfunction (CMD) [11]. This may partly 
relate to anatomical differences in coronary diameter, higher 
coronary blood flow, and higher endothelial shear stress [12].
The gold standard for the measurement of the cardiac 
microvascular function and myocardial blood flow/perfusion 
is dynamic positron emission tomography/computed tomog-
raphy (PET/CT) imaging, which enables the quantification of 
absolute myocardial perfusion in mL/g/min by intravenous 
injection of a perfusion positron–emitting tracer. Therefore, we 
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conducted the first comparison of the cardiac microvascular 
function quantified as the myocardial flow reserve (MFR) by 
82Rb PET between WLWH and MLWH. The MFR quantifies the 
vasodilator function of the cardiac circulation, and in the gen-
eral population, a decreased MFR has shown to be associated 
with major adverse cardiac events (MACEs) among women 
even in the absence of obstructive coronary disease [13, 14]. In 
addition, we studied CMV IgG quantified in plasma to inves-
tigate the hypothesis that CMV IgG could influence cardiac 
microvascular function.
METHODS
Participants
MLWH were recruited from a previously described cohort [15], 
and perfusion data have been presented elsewhere [16]. WLWH 
were all recruited from the Study on HIV, cervical Abnormalities 
and infections in women in Denmark (SHADE), as described 
elsewhere [17]. Inclusion criteria were age ≥18 years and ART 
>12 months. Exclusion criteria were (i) asthma, (ii) pregnancy, 
or (iii) alcohol or drug abuse that could affect the ability to 
adhere to the protocol. Ninety-four PLWH comprising 50 men 
and 44 women underwent 82Rb PET/CT between August 2012 
and February 2014.
Ethics
The study was approved by the Scientific Ethics Committee of 
the Capital Region of Denmark (protocol number H-C-2008–
060) and complied with the Declaration of Helsinki. All study 
participants received oral and written information and gave 
written consent before inclusion.
PET Imaging
The detailed methodology of the 82Rb PET/CT myocardial 
perfusion imaging (MPI) has been described previously [16]. 
In brief, all study participants were asked to abstain from caf-
feine and theophylline-containing substances and medications 
for 12 hours before imaging, and abstinence was confirmed 
before the examination. Electrocardiography-gated MPI was 
performed during rest and stress conditions in a single session 
on a Siemens Biograph mCT/PET 128-slice scanner (Siemens 
Helthcare, Knoxville, TN). Study participants were stressed 
using adenosine for 6 minutes, and the stress 82Rb infusion was 
initiated 2.5 minutes after the start of the adenosine infusion. 
Low-dose CT for attenuation correction was performed before 
the rest study and after the stress study if required. Coronary 
artery calcium score (CACS) images were acquired as per clin-
ical routine from a noncontrast breath-hold CT. The CACS was 
calculated according to the Agatston score using a threshold of 
130 Hounsfield units (HU) [18]. Quantitative myocardial blood 
flow (MBF) was performed using syngo software (Siemens 
Healthcare, Knoxville, TN), which is based on a single-compart-
ment model for 82Rb kinetics [19] to obtain the absolute MBF 
in milliliters per gram of tissue per minute. MFR was defined as 
MBF during maximal hyperemia (stress), obtained by the infu-
sion of adenosine divided by MBF during rest. The MFR was 
corrected for baseline cardiac work by dividing the rest MBF 
by the rate pressure product (RPP), which is the systolic blood 
pressure times the heart rate, multiplied by 10 000 [20]. MFR 
was considered normal if ≥2.0, and values <2.0 reflected CMD 
for both men and women [13].
Semiquantitative analysis for detection of perfusion defects 
was computed as a summed stress score (SSS) according to the 
AHA 17 myocardial segment model [21] automatically with 
Corridor4DM (INVIA, Ann Arbor, MI). An SSS was consid-
ered abnormal if >4 [22]. Left ventricular ejection fraction 
(LVEF) was calculated automatically with Corridor4DM.
Biomarkers and CVD Risk Score
CD4 cell counts, HIV RNA levels, creatinine, and serum lipids 
were determined routinely on blood and plasma when collected 
and information obtained from the study participants’ medi-
cal records. Information on comorbidities and medication was 
obtained by questionnaire and medical records. Framingham 
risk score (FRS) was calculated as the 10-year risk of coronary 
heart disease according to published definitions [23].
All study participants had plasma samples taken in a fasting 
state at the time of PET/CT and stored at –80°C until analysis 
of CMV IgG, which was performed by an automatic instrument 
(COBAS6000, Roche Diagnostics GmbH, and Mannheim, 
Germany) using an electro-chemiluminescence assay (cobas, 
Roche Diagnostics GmbH, Mannheim, Germany). The test 
results are quantitative and are provided in units/mL (U/mL).
The testing was performed according to the recommenda-
tions of the manufacturer.
Statistics
Data are shown as mean ± standard error of the mean or 
median (range). Continuous variables were compared using 
an unpaired t test after log10-transformation to obtain a nor-
mal distribution. Categorical variables were compared by 
chi-square test. Associations were analyzed with both logistic 
(categorical variables) and multiple linear regression (continu-
ous variables after log10-transformation) models. In the multiple 
regression analysis, adjustments were made for factors known 
to be involved in CVD and cardiac microvascular function, that 
is, FRS (including age, active smoking, diabetes, systolic blood 
pressure, total cholesterol, and high-density lipoprotein), kidney 
function (measured as creatinine), positive CACS, and use of 
lipid-lowering medication and/or antihypertensive medication. 
Test for interaction was performed with a general linear model. 
With a total of 94 participants in the 2 groups, we obtained a 
power of 0.8 to detect a difference of 0.4 in MFR (alpha, 0.05) 
using previously published standard deviations from MPI data 
using 82Rb and adenosine on the same scanner [24].
All statistics were performed using SPSS 22 (IBM SPSS 
Statistics for Windows, version 22.0; IBM Corp., Armonk, NY).
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RESULTS
The characteristics of the 2 groups are shown in Table 1. From 
this table, some differences should be noted; for example, the 
women were almost 10 years younger, were less likely to be on 
lipid-lowering or antihypertensive treatment, and had a more 
“favorable” lipid profile and lower creatinine. Also, the FRS was 
significantly lower among women. However, men and women 
did not differ significantly regarding active smoking, and their 
body mass index (BMI) was very similar (borderline over-
weight). Ninety-eight percent of the men included were white, 
whereas race was more diverse in the female group. Ninety-six 
and 98% of the men and women, respectively, were CMV sero-
positive, all with avidity >80%, and their CMV IgG concentra-
tions did not differ significantly.
HIV Parameters
All participants included in the study received ART, ~95% had 
CD4 cell counts >350 106/L, and >90% had viral loads <20 cop-
ies/mL. The ART regimens were very similar among men and 
women, except that women were more likely to receive inte-
grase inhibitors (Table 2).
Myocardial Blood Flow and Myocardial Flow Reserve
The women had significantly higher MBF at both stress and rest, 
and when corrected for baseline cardiac work. However, their 
mean MFR was significantly lower than that of men (2.13 ± 0.10 vs 
2.57 ± 0.11; P = .003). Significantly more women had an MFR <2 
(45% vs 24%; P = .03) (Table 3 and Figure 1). Race did not influence 
the MFR (P = .92), nor was an association found between age and 
MFR (β = –.003, P = .25 for men; β = –.002, P = .45 for women).
HIV-specific variables had no impact on the MFR: CD4 nadir 
(β = –.03, P = .55 for men; β = .004, P = .93 for women), current 
CD 4 cell count (β = –.05, P = .67 for men; β = –.03, P = .80 for 
women), duration of ART (β = .002, P = .60 for men; β = 0.001, 
P = .90 for women). No significant interaction between sex and 
the covariates was found.
Twenty-two percent of the men and 14% of the women had 
an SSS >4 (P =  .23), and in sensitivity analyses that excluded 
Table 1. Baseline Characteristics
Parameter Men Women P Value
No. 50 44
Age, mean ± SEM, y 53 ± 1 45 ± 1 <.001
Race, No. (%) <.001
 White 49 (98) 21 (48)
 Black 0 13 (29)
 Asian 0 9 (21)
 Other 1 (2) 1 (2)
Active smoking, No. (%) 12 (24) 6 (14) .16
BMI, mean ± SEM, kg/m2 24.9 ± 0.5 24.6 ± 0.8 .74
Medication, No. (%)
 Antihypertensive 18 (36) 8 (18) .04
 Statin 13 (26) 3 (7) .01
 Antidiabetics 1 (2) 2 (5) .45
Clinical CVD, No. (%)a 2 (4) 0 (0) .28
FRS, CHD 10 y, mean ± SEM, % 10.3 ± 0.8 2.7 ± 0.4 <.001
Lipids, mean ± SEM, mmol/L
 Total cholesterol 5.7 ± 0.1 5.4 ± 0.2 .21
 HDL 1.4 ± 0.1 1.7 ± 0.1 .02
 LDL 3.4 ± 0.1 3.1 ± 0.1 .09
Blood pressure, mean ± SEM, mmHg
 Systolic 127 ± 2 124 ± 3 .51
 Diastolic 70 ± 1 80 ± 2 <.001
Creatinine, mean ± SEM, 
μmol/L
80 ± 2 63 ± 2 <.001
Hepatitis, No. (%)b
 Chronic hepatitis B 3 (6) 2 (5) .56
 Chronic hepatitis C 1 (2) 3 (7) .26
Cytomegalovirus, No. (%)
 CMV positive 48 (96) 43 (98) .55
CMV IgG, median (range), U/mLc 123 (25–924) 89 (34–372) .22
Abbreviations: BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; FRS, Framingham risk score; HDL, high-density lipoprotein; LDL, low-density lipopro-
tein; SEM, standard error of the mean.
aDefined as history of myocardial infarction, transient ischaemic attack/stroke, angina, peripheral arterial disease, or revascularization procedure. 
bDefined as HBsAg positive and hepatitis C IgG positive. 
cCMV positive only.
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subjects with an SSS >4, reflecting obstructive coronary 
artery disease, the mean MFR remained lower among women 
(2.17 ± 0.11 vs 2.61 ± 0.13; P = .014).
Cytomegalovirus IgG and MFR
A significant negative association was found between CMV IgG 
and MBF at stress among the women (β = –.20, P = .003) but not 
men (β = .03, P = .59, P for interaction = .01), whereas no asso-
ciation was found for CMV IgG and MBF at rest. In the group of 
women, a trend for decrease in MFR with an increase in CMV IgG 
was found; however, it was not significant (β = –.15, P = .12). No 
association was found among men (β = –.02, P = .77) (Figure 2).
In a multiple regression analysis adjusting for possible con-
founders of MFR, we found a significant negative association 
of CMV IgG and MFR among women (β = –.33, P = .004) but 
not men (β  =  .03, P  =  .73). In this analysis, a borderline sig-
nificant interaction between sex and CMV IgG was found (P 
for interaction = .05). CMV IgG was not associated with risk of 
having a positive CACS or SSS >4 in either group (odds ratio 
[OR] per log10 increase in CMV IgG for women: OR, 0.1–25 
for positive CACS and 0.1–27 for SSS >4; men: OR, 0.6–85 for 
positive CACS and 0.4–40 for SSS >4).
DISCUSSION
In this first study to compare cardiac microvascular function 
between women and men living with HIV, we found that the 
MFR in WLWH with viral suppression, normal CD4 cell counts, 
Table 3. Data From the 82-Rubidium PET/CT Scan
Parameter Men (n = 50) Women (n = 44) P Value
Positive CACS, No. (%) 20 (40) 7 (16) .01
CACS, median (range)a 123 (1–1884) 130 (22–599) .74
Rest Rb-PET
Rate-pressure product, mean ± SEM 8742 ± 242 8030 ± 400 .12
LVEF, mean ± SEM, % 54 ± 1 66 ± 1 <.001
Stress Rb-PET
Rate-pressure product, mean ± SEM 10 558 ± 403 10 231 ± 504 .61
LVEF, mean ± SEM, % 60 ± 1 71 ± 1 <.001
LVEF increase, mean ± SEM, % 13 ± 1 9 ± 1 .04
Perfusion data
MBF rest, mean ± SEM, mL/g/min 0.89 ± 0.03 1.23 ± 0.05 <.001
MBF rest RPP corrected, mean ± SEM, mL/g/min 1.03 ± 0.03 1.56 ± 0.05 <.001
MBF stress, mean ± SEM, mL/g/min 2.61 ± 0.09 3.2 ± 0.10 <.001
MFR, mean ± SEM 2.57 ± 0.11 (n = 46) 2.13 ± 0.10 (n = 42) .003
MFR <2, No. (%) 11 (24) 19 (45) .03
SSS >4, No. (%) 11 (22) 6 (14) .23
Abbreviations: CACS, coronary artery calcium score; LVEF, left ventricular ejection fraction; MBF, myocardial blood flow; MFR, myocardial flow reserve; PET/CT, positron emission tomogra-
phy/computed tomography; SEM, standard error of the mean; SSS, summed stress score.
aFor the CACS positive only.
Table 2. HIV-Related Characteristics
Parameter Men Women P Value
CD4 cell count, median (range), 106/L 645 (285–1390) 644 (222–1780) .45
CD4 cell count >350 106/L, No. (%) 47 (94) 42 (95) .60
Nadir CD4 cell count, median (range), 106/L 157 (0–606) 156 (3–553) .78
HIV RNA, median (range), copies/mL 19 (19–39) 19 (19–36) .71
HIV RNA ≤20 copies/mL, No. (%) 47 (94) 41 (93) .59
HIV duration, mean ± SEM, y 16.5 ± 1 14.4 ± 1 .13
ART duration, mean ± SEM, y 12.6 ± 0.6 11.2 ± 0.7 .13
ART regimens, No. (%)
≥2 NRTIs + ≥1 NNRTI 31 (62) 24 (55) .31
≥2 NRTIs + PI 13 (26) 11 (25) .55
PI only 3 (6) 1 (2) .36
INI 2 (4) 6 (14) .09
Other 1 (2) 2 (5) .54
Abbreviations: ART, antiretroviral treatment; INI, integrase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease 
inhibitor; SEM, standard error of the mean.
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and very low cardiovascular risk scores was significantly lower 
than in MLWH. Forty-five percent of the women included in 
this study had an MFR <2, indicating that the increased risk of 
CVD among WLWH could be explained by a compromise in 
cardiac microvascular function. Further, the decrease in micro-
vascular function appeared to be associated with CMV IgG.
In the general population, MFR has a high predictive power 
for future cardiovascular events [25–27], and it seems that the 
MFR is a more reliable measure than MBF alone in both risk 
prediction and reclassification ability [25, 26, 28]. Importantly, 
the prognostic ability of MFR is unaffected by sex [13, 14]. In 
a large study of 1218 patients including 813 women with no 
signs of obstructive coronary artery disease on semiquantita-
tive visual analysis followed for a median of 1.3 years, MACE 
occurred earlier and more frequently among both men and 
women with CMD, defined as MFR <2.0, than in those without 
CMD regardless of sex [13].
We found that the women in our study had a mean MFR 
comparable to that of a cohort of 107 women with angina from 
the iPOWER study who underwent 82Rb PET/CT on the same 
scanner with identical acquisition, reconstruction protocols, 
and cardiac image analysis software during the same period [29]. 
The mean age in that study was 61.8 years, and cardiovascular 
risk factors were more prevalent. These patients had a median 
MFR (interquartile range) of 2.13 (1.80–2.40), very similar to 
the WLWH in the present study who had a mean MFR of 2.13 
despite being more than 15 years younger and having no appar-
ent risk of CVD.
Few studies have looked at cardiac vasomotor function 
in PLWH. Two previous studies found that MLWH with low 
CVD risk have MFRs comparable to HIV-uninfected men 
[16, 30]. On the other hand, a recent study of PLWH both with 
and without CAD found that PLWH (63% men) without CAD 
had coronary endothelial function, as assessed by coronary 
MRI, comparable to HIV-uninfected patients with CAD, with 
no obvious influence of sex [31]. These studies used different 
imaging modalities, including cardiac stress testing protocols, 
which arguably could lead to different results. Studies looking 
specifically at subclinical CVD in WLWH have found a higher 
prevalence of carotid lesions than in HIV-uninfected women 
but comparable to MLWH [32]. However, a recent study of 
subclinical coronary lesions in PLWH on ART found that the 
prevalence of any type of coronary lesion (including high-risk 
plaques) among WLWH was significantly lower than among 
MLWH. The authors suggest that the increased risk of CVD 
among WLWH despite lower prevalence of coronary lesions 
could be explained by microvascular disease [33]. Our study 
supports this theory and extends the findings by suggesting 
a pathophysiologic role of CMV. In the general population, 
CMV has been associated with endothelial dysfunction [34] 
and detected within atherosclerotic plaques [35], and a recent 
meta-analysis found that CMV infection is associated with an 
increased risk of CVD [36]. Among PLWH, co-infection with 
CMV is higher than in the general population [8] and seems 
to cause an immune response involved in the pathogenesis of 
CVD [8, 37].
However, in this study, we only found an association between 
MFR and CMV among women. Therefore, questions arise per-
taining to the difference in sex. Do women react differently to 
CMV IgG regarding vascular pathology, or is the CMV IgG cor-
related with more inflammation in WLWH? Indeed, some stud-
ies suggest that inflammation and immune dysfunction may be 
more prevalent in WLWH compared with MLWH [38, 39].
Our study is limited by the inability to investigate soluble 
markers of inflammation, and further studies are therefore 
warranted to explore how chronic inflammation influences car-
diac microvascular function in PLWH. Also, the quantification 
of CMV IgG only reflects 1 aspect of co-infection with CMV, 
which is a highly immunogenic virus with impact on both the 
cellular and adaptive immune systems. Underlying immuno-
logical and inflammatory perturbations may therefore have 
gone unaccounted for in this study.
Finally, we did not have data on menopause, nor did we have 
the possibility to measure endogenous sex hormone production. 
5
4
3
2
1
0
m
L
/g
/m
in
Rest MBF Stress MBF MFR
* * *
5
4
3
2
1
0
Men
Women
Figure 1. Levels of myocardial blood flow (MBF) at rest and stress in mL/g/min 
and the unit less myocardial flow reserve (MFR; right y-axis) in men and women 
living with HIV. *P < .05.
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This could be of importance as endogenous estrogen produc-
tion may protect women against CVD [40] and perturbation 
of sex hormone levels has been proposed to impact the risk of 
CVD among WLWH [41].
On the other hand, age was not associated with MFR in this 
study, and when comparing a premenopausal and (peri)men-
opausal group dichotomized at 47  years [42], we found no 
difference in MFR. This indicates that cardiac microvascular 
dysfunction seems to affect WLWH at all ages. In this cross-
sectional study, we were unable to determine if the low MFR 
found among the women will translate into clinical CVD and/
or MACE.
CONCLUSION
In this first study comparing MFR using 82Rb PET MPI in 
women and men living with HIV on stable ART, we found that 
WLWH had significantly lower MFR than MLWH who were 
older and had more cardiovascular risk factors. The MFR found 
among WLWH was comparable to that of a previously pub-
lished cohort of HIV-uninfected women with angina, who were 
more than 15  years older and had higher CVD risk. Further, 
our study indicates an association between CMV infection 
and the observed sex difference in MFR. These findings call 
for further studies into both the prevalence and pathogenesis 
of cardiac microvascular dysfunction in WLWH, especially as 
traditional cardiovascular screening tools do not readily cap-
ture this pathology. Finally, this study underlines the need for 
continued awareness of the increased cardiovascular risk found 
among WLWH of young age and low predicted risk scores.
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